Gentian Diagnostics AS
GENT
Rank in Stocks
#21631
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents... Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.
Share Price
$4.16
Last synced: 2026-11-12
Market Cap
$64.37M
Change (1 day)
-0.02%
Change (1 year)
-24.65%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Gentian Diagnostics AS (GENT)
Category
Healthcare
Operating Margin for Gentian Diagnostics AS (GENT)
Operating Margin as of November 2026 TTM: -2.24%
According to Gentian Diagnostics AS's latest financial reports, its current operating margin (TTM) is -2.24%. At the end of 2025 the company had an operating margin of 11.73%.
Operating Margin history for Gentian Diagnostics AS from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -2.24% | -119.10% |
| 2025 | 11.73% | 13.44% |
| 2024 | 10.34% | -210.35% |
| 2023 | -9.37% | -59.01% |
| 2022 | -22.86% | -16.84% |
| 2021 | -27.49% | 5.45% |
| 2020 | -26.07% | -53.96% |
| 2019 | -56.63% | 26.24% |
| 2018 | -44.86% | -3.11% |
| 2017 | -46.30% | 42.24% |
| 2016 | -32.55% | 340.46% |
| 2015 | -7.39% | 58.58% |
| 2014 | -4.66% | -191.55% |
| 2013 | 5.09% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 18.91% | -108.44% |
IE
|
|
| 10.95% | -104.89% |
CN
|
|
| 25.26% | -111.28% |
CH
|
|
| 13.54% | -106.04% |
CH
|
|
| 38.62% | -117.24% |
CN
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Gentian Diagnostics AS's operating margin
What is Gentian Diagnostics AS's operating margin?
Gentian Diagnostics AS's operating margin is -2.24%, as of Nov 2026.
What was Gentian Diagnostics AS's operating margin in 2025?
In 2025, Gentian Diagnostics AS's operating margin was 11.73%, compared with 10.34% in 2024.
How has Gentian Diagnostics AS's operating margin changed since 2020?
From 2020 to 2025, Gentian Diagnostics AS's operating margin was highest in 2025 (11.73%) and lowest in 2021 (-27.49%).
How does Gentian Diagnostics AS's operating margin compare with similar companies?
Gentian Diagnostics AS's operating margin (-2.24%) is lower than that of all 5 similar companies listed above. The highest among them is Jafron Biomedical Co.,Ltd., with 38.62%.